抄録
Clinical effectiveness and safety of CFIX for paranasal sinusitis was studied according to the same protocol in cooperation with multi-clinics. 1. Twenty-seven adult or infant patients entered into the trial and they consisted of 25 cases with acute sinusitis and 2 with acute exacerbation of chronic sinusitis. 2. The efficacy rate judged by the doctor in charge was 66.7% (18/27), by the unified criteria was 74.1% (20/27). 3. The bacteriological responses were evaluated in 18 cases. The elimination rate was 94.4% (17/18). 4. As the side effect, slight stomach discomfort was observed in 1 case out of 27 cases (3.7%). No abnormal laboratory findings were observed. From the above results, CFIX was considered to be a useful drug in the treatment for paranasal sinusitis.
